KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Income towards Common Stockholders (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Net Income towards Common Stockholders for 13 consecutive years, with -$111.4 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 57.67% to -$111.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$352.1 million through Dec 2025, down 47.12% year-over-year, with the annual reading at -$352.1 million for FY2025, 50.25% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$111.4 million at Xenon Pharmaceuticals, down from -$90.9 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$15.1 million in Q3 2021, with the low at -$111.4 million in Q4 2025.
  • Average Net Income towards Common Stockholders over 5 years is -$48.8 million, with a median of -$46.1 million recorded in 2023.
  • The sharpest move saw Net Income towards Common Stockholders crashed 12598.82% in 2021, then fell 14.87% in 2024.
  • Over 5 years, Net Income towards Common Stockholders stood at -$25.1 million in 2021, then crashed by 49.05% to -$37.4 million in 2022, then fell by 19.7% to -$44.7 million in 2023, then tumbled by 57.96% to -$70.7 million in 2024, then plummeted by 57.67% to -$111.4 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$111.4 million, -$90.9 million, and -$84.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.